Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 346
Last updated 2023-06-06
Summary
The purpose of this study is to develop a test for detection of pancreatic cancer by looking at the subject's DNA.
Conditions
Interventions
- DRUG
-
Synthetic Human Secretin
Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Massimo Raimondo, MD · Mayo Clinic
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-11
- Primary Completion
- 2022-03-10
- Completion
- 2022-03-10
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer
NCT04616131 ·Status: UNKNOWN
-
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
NCT06043921 ·Status: RECRUITING
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07096362 ·Status: RECRUITING ·Phase: PHASE2
-
Pancreatic Adenocarcinoma Gene Environment Risk Study
NCT00912717 ·Status: RECRUITING
-
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
NCT00897832 ·Status: COMPLETED
-
Blood Markers of Early Pancreas Cancer
NCT03568630 ·Status: RECRUITING
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
NCT03060720 ·Status: ACTIVE_NOT_RECRUITING
-
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
NCT07122466 ·Status: ACTIVE_NOT_RECRUITING
-
Biomarkers Study in Pancreatic Cancer
NCT01666184 ·Status: UNKNOWN
-
A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer
NCT03902600 ·Status: ACTIVE_NOT_RECRUITING
-
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
NCT06320717 ·Status: RECRUITING
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Early Detection of Pancreatic Cancer
NCT05596435 ·Status: UNKNOWN
-
ctDNA Assay in Patients With Resectable Pancreatic Cancer
NCT05052671 ·Status: RECRUITING
-
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
NCT06807112 ·Status: NOT_YET_RECRUITING
-
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 ·Status: ACTIVE_NOT_RECRUITING
-
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
NCT06478056 ·Status: COMPLETED ·Phase: NA
-
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
NCT03536793 ·Status: RECRUITING
-
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
NCT06397846 ·Status: RECRUITING ·Phase: NA
-
Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer
NCT00559598 ·Status: COMPLETED
-
Early Detection of PDAC in Patients With Chronic Pancreatitis
NCT07104864 ·Status: COMPLETED
-
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616 ·Status: TERMINATED ·Phase: NA
-
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT02478892 ·Status: RECRUITING
-
Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer
NCT05848154 ·Status: NOT_YET_RECRUITING